TMR 조사 보고서 '세계의 건선 치료 시장'은 2025-2035년 예측 기간 동안 시장 지표에 대한 가치 있는 인사이트를 얻기 위해 과거 및 현재의 성장 동향과 기회를 연구합니다. 2025년 기준 연도, 2035년 예측연도로, 2025-2035년 세계의 건선 치료 시장 수익과 예측을 제공합니다. 또한 2025-2035년 세계의 건선 치료 시장 연평균 성장률(CAGR%)도 제공합니다.
본 보고서는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 KOL(Key Opinion Leader), 업계 리더, 의견 형성자들과 인터뷰를 실시했습니다. 2차 연구는 주요 업체들의 제품 문헌, 연차 보고서, 보도 자료 및 관련 문서를 참조하여 건선 치료 시장을 파악했습니다.
시장 현황
시장 매출(2024년)
350억 달러
시장 매출(2035년)
876억 달러
CAGR
9.5%
본 보고서는 세계의 건선 치료 시장 경쟁 구도를 조사했습니다. 세계의 건선 치료 시장에서 사업을 전개하는 주요 기업을 식별하고 각각을 다양한 속성으로 프로파일하고 있습니다. 기업 개요, 재무 현황, 최근 동향, SWOT 분석은 본 보고서에서 프로파일링된 세계의 건선 치료 시장 참여 기업 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
소개
개요
시장 역학
세계의 건선 치료 시장 분석과 예측(2020-2035년)
제5장 주요 인사이트
주요 지역 및 국가 규제 상황
건선 치료 시장 동향
Porter's Five Forces 분석
PESTEL 분석
최종 사용자를 위한 주요 구매 지표
브랜드와 가격 분석
치료 알고리즘
유통업체의 정세
제6장 세계 시장 분석과 예측 : 약제 유형별
소개 및 정의
주요 조사 결과 및 진전
시장 매출 예측 : 약제 유형별(2020-2035년)
생물학적 제형
TNF 억제제
인터루킨 억제제
IL-17 억제제
IL-23 억제제
기타
저분자 의약품
티로신 키나아제 2(TYK2) 억제제
포스포디에스테라아제 4(PDE4) 억제제
코르티코스테로이드
레티노이드
칼시뉴린 억제제
기타
시장의 매력 : 약제 유형별
제7장 세계 시장 분석과 예측 : 유형별
소개 및 정의
주요 조사 결과 및 진전
시장 매출 예측 : 유형별(2020-2035년)
브랜드
제네릭
시장의 매력 : 유형별
제8장 세계 시장 분석과 예측 : 건선 유형별
소개 및 정의
주요 조사 결과 및 진전
시장 매출 예측 : 건선 유형별(2020-2035년)
판상 건선
역건선
점상 건선
농포성 건선
기타
시장의 매력 : 건선 유형별
제9장 세계 시장 분석과 예측 : 투여 경로별
소개 및 정의
주요 조사 결과 및 진전
시장 매출 예측 : 투여 경로별(2020-2035년)
경구
국소
비경구
시장의 매력 : 투여 경로별
제10장 세계 시장 분석과 예측 : 유통 채널별
소개 및 정의
주요 조사 결과 및 진전
시장 매출 예측 : 유통 채널별(2020-2035년)
병원 약국
소매 약국
온라인 약국
시장의 매력 : 유통 채널별
제11장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 : 지역별
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 : 지역별
제12장 북미 시장 분석과 예측
미국
캐나다
제13장 유럽 시장 분석과 예측
독일
영국
프랑스
이탈리아
스페인
스위스
네덜란드
기타 유럽
제14장 아시아태평양 시장 분석과 예측
중국
일본
인도
호주 및 뉴질랜드
한국
기타 아시아태평양
제15장 라틴아메리카 시장 분석과 예측
브라질
멕시코
아르헨티나
기타 라틴아메리카
제16장 중동 및 아프리카 시장 분석과 예측
GCC 국가
남아프리카
기타 중동 및 아프리카
제17장 경쟁 구도
시장 기업 : 경쟁 매트릭스(기업 등급별, 규모별)
시장 점유율 분석 : 기업별(2024년)
기업 프로파일
Bristol-Myers Squibb Company
AbbVie Inc
Amgen Inc
AstraZeneca
Eli Lilly and Company
Johnson & Johnson Services, Inc.
LEO Pharma A/S
Merck & Co., Inc.,
Novartis AG
Boehringer Ingelheim Pharmaceuticals, Inc.
Arcutis Biotherapeutics, Inc
Dermavant Sciences, Inc.
TIEFENBACHER GROUP
UCB SA
Bausch Health
Sun Pharmaceutical Industries Limited
Akeso Biopharma Co., Ltd.
HBR
영문 목차
영문목차
Psoriasis Treatment Market- Scope of Report
TMR's report on the global Psoriasis Treatment Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Psoriasis Treatment Market for the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Psoriasis Treatment Market from 2025 to 2035.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Psoriasis Treatment Market .
Market Snapshot
Market Value in 2024
US$ 35 Bn
Market Value in 2035
US$ 87.6 Bn
CAGR
9.5%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Psoriasis Treatment Market .
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Psoriasis Treatment Market. These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Psoriasis Treatment Market .
The report delves into the competitive landscape of the global Psoriasis Treatment Market. Key players operating in the global Psoriasis Treatment Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Psoriasis Treatment Market profiled in this report.
Key Questions Answered in Global Psoriasis Treatment Market Report:
What are the opportunities in the global Psoriasis Treatment Market ?
What are the major drivers, restraints, opportunities, and threats in the Market ?
Which regional Market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the Market positions of different companies operating in the global Market ?
Psoriasis Treatment Market- Research Objectives and Research Approach
The comprehensive report on the global Psoriasis Treatment Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Psoriasis Treatment Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Psoriasis Treatment Market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Psoriasis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Psoriasis Treatment Market Analysis and Forecasts, 2020 to 2035
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Regulatory Landscape across Key Regions / Countries
5.2. Psoriasis Treatment Market Trends
5.3. PORTER's Five Forces Analysis
5.4. PESTEL Analysis
5.5. Key Purchase Metrics for End-users
5.6. Brand and Pricing Analysis
5.7. Treatment Algorithm
5.8. Distributors Landscape
6. Global Psoriasis Treatment Market Analysis and Forecasts, By Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Type, 2020 to 2035
6.3.1. Biologics
6.3.1.1. TNF Inhibitors
6.3.1.2. Interleukin Inhibitors
6.3.1.2.1. IL-17 Inhibitors
6.3.1.2.2. IL-23 Inhibitors
6.3.1.2.3. Others
6.3.2. Small Molecule Drugs
6.3.2.1. Tyrosine kinase 2 (TYK2) inhibitors
6.3.2.2. Phosphodiesterase 4 (PDE4) inhibitor
6.3.2.3. Corticosteroids
6.3.2.4. Retinoids
6.3.2.5. Calcineurin inhibitors
6.3.2.6. Others
6.4. Market Attractiveness By Drug Type
7. Global Psoriasis Treatment Market Analysis and Forecasts, By Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Type, 2020 to 2035
7.3.1. Branded
7.3.2. Generic
7.4. Market Attractiveness By Type
8. Global Psoriasis Treatment Market Analysis and Forecasts, By Types of Psoriasis
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Types of Psoriasis, 2020 to 2035
8.3.1. Plaque Psoriasis
8.3.2. Inverse Psoriasis
8.3.3. Guttate Psoriasis
8.3.4. Pustular Psoriasis
8.3.5. Others
8.4. Market Attractiveness By Types of Psoriasis
9. Global Psoriasis Treatment Market Analysis and Forecasts, By Route of Administration
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Route of Administration, 2020 to 2035
9.3.1. Oral
9.3.2. Topical
9.3.3. Parenteral
9.4. Market Attractiveness By Route of Administration
10. Global Psoriasis Treatment Market Analysis and Forecasts, By Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By Distribution Channel, 2020 to 2035
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness By Distribution Channel
11. Global Psoriasis Treatment Market Analysis and Forecasts, By Region
11.1. Key Findings
11.2. Market Value Forecast By Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness By Region
12. North America Psoriasis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Type, 2020 to 2035
12.2.1. Biologics
12.2.1.1. TNF Inhibitors
12.2.1.2. Interleukin Inhibitors
12.2.1.2.1. IL-17 Inhibitors
12.2.1.2.2. IL-23 Inhibitors
12.2.1.2.3. Others
12.2.2. Small Molecule Drugs
12.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors
12.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor
12.2.2.3. Corticosteroids
12.2.2.4. Retinoids
12.2.2.5. Calcineurin inhibitors
12.2.2.6. Others
12.3. Market Value Forecast By Type, 2020 to 2035
12.3.1. Branded
12.3.2. Generic
12.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035
12.4.1. Plaque Psoriasis
12.4.2. Inverse Psoriasis
12.4.3. Guttate Psoriasis
12.4.4. Pustular Psoriasis
12.4.5. Others
12.5. Market Value Forecast By Route of Administration, 2020 to 2035
12.5.1. Oral
12.5.2. Topical
12.5.3. Topical
12.6. Market Value Forecast By Distribution Channel, 2020 to 2035
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Value Forecast By Country, 2020 to 2035
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Drug Type
12.8.2. By Type
12.8.3. By Types of Psoriasis
12.8.4. By Route of Administration
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Psoriasis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Type, 2020 to 2035
13.2.1. Biologics
13.2.1.1. TNF Inhibitors
13.2.1.2. Interleukin Inhibitors
13.2.1.2.1. IL-17 Inhibitors
13.2.1.2.2. IL-23 Inhibitors
13.2.1.2.3. Others
13.2.2. Small Molecule Drugs
13.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors
13.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor
13.2.2.3. Corticosteroids
13.2.2.4. Retinoids
13.2.2.5. Calcineurin inhibitors
13.2.2.6. Others
13.3. Market Value Forecast By Type, 2020 to 2035
13.3.1. Branded
13.3.2. Generic
13.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035
13.4.1. Plaque Psoriasis
13.4.2. Inverse Psoriasis
13.4.3. Guttate Psoriasis
13.4.4. Pustular Psoriasis
13.4.5. Others
13.5. Market Value Forecast By Route of Administration, 2020 to 2035
13.5.1. Oral
13.5.2. Topical
13.5.3. Topical
13.6. Market Value Forecast By Distribution Channel, 2020 to 2035
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Switzerland
13.7.7. The Netherlands
13.7.8. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Drug Type
13.8.2. By Type
13.8.3. By Types of Psoriasis
13.8.4. By Route of Administration
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Psoriasis Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Drug Type, 2020 to 2035
14.2.1. Biologics
14.2.1.1. TNF Inhibitors
14.2.1.2. Interleukin Inhibitors
14.2.1.2.1. IL-17 Inhibitors
14.2.1.2.2. IL-23 Inhibitors
14.2.1.2.3. Others
14.2.2. Small Molecule Drugs
14.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors
14.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor
14.2.2.3. Corticosteroids
14.2.2.4. Retinoids
14.2.2.5. Calcineurin inhibitors
14.2.2.6. Others
14.3. Market Value Forecast By Type, 2020 to 2035
14.3.1. Branded
14.3.2. Generic
14.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035
14.4.1. Plaque Psoriasis
14.4.2. Inverse Psoriasis
14.4.3. Guttate Psoriasis
14.4.4. Pustular Psoriasis
14.4.5. Others
14.5. Market Value Forecast By Route of Administration, 2020 to 2035
14.5.1. Oral
14.5.2. Topical
14.5.3. Topical
14.6. Market Value Forecast By Distribution Channel, 2020 to 2035
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. South Korea
14.7.6. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Drug Type
14.8.2. By Type
14.8.3. By Types of Psoriasis
14.8.4. By Route of Administration
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Psoriasis Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Drug Type, 2020 to 2035
15.2.1. Biologics
15.2.1.1. TNF Inhibitors
15.2.1.2. Interleukin Inhibitors
15.2.1.2.1. IL-17 Inhibitors
15.2.1.2.2. IL-23 Inhibitors
15.2.1.2.3. Others
15.2.2. Small Molecule Drugs
15.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors
15.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor
15.2.2.3. Corticosteroids
15.2.2.4. Retinoids
15.2.2.5. Calcineurin inhibitors
15.2.2.6. Others
15.3. Market Value Forecast By Type, 2020 to 2035
15.3.1. Branded
15.3.2. Generic
15.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035
15.4.1. Plaque Psoriasis
15.4.2. Inverse Psoriasis
15.4.3. Guttate Psoriasis
15.4.4. Pustular Psoriasis
15.4.5. Others
15.5. Market Value Forecast By Route of Administration, 2020 to 2035
15.5.1. Oral
15.5.2. Topical
15.5.3. Topical
15.6. Market Value Forecast By Distribution Channel, 2020 to 2035
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Online Pharmacies
15.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Argentina
15.7.4. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Drug Type
15.8.2. By Type
15.8.3. By Types of Psoriasis
15.8.4. By Route of Administration
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Psoriasis Treatment Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast By Drug Type, 2020 to 2035
16.2.1. Biologics
16.2.1.1. TNF Inhibitors
16.2.1.2. Interleukin Inhibitors
16.2.1.2.1. IL-17 Inhibitors
16.2.1.2.2. IL-23 Inhibitors
16.2.1.2.3. Others
16.2.2. Small Molecule Drugs
16.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors
16.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor
16.2.2.3. Corticosteroids
16.2.2.4. Retinoids
16.2.2.5. Calcineurin inhibitors
16.2.2.6. Others
16.3. Market Value Forecast By Type, 2020 to 2035
16.3.1. Branded
16.3.2. Generic
16.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035
16.4.1. Plaque Psoriasis
16.4.2. Inverse Psoriasis
16.4.3. Guttate Psoriasis
16.4.4. Pustular Psoriasis
16.4.5. Others
16.5. Market Value Forecast By Route of Administration, 2020 to 2035
16.5.1. Oral
16.5.2. Topical
16.5.3. Topical
16.6. Market Value Forecast By Distribution Channel, 2020 to 2035
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Online Pharmacies
16.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Drug Type
16.8.2. By Type
16.8.3. By Types of Psoriasis
16.8.4. By Route of Administration
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis By Company (2024)
17.3. Company Profiles
17.3.1. Bristol-Myers Squibb Company
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategies
17.3.1.5. Recent Developments
17.3.2. AbbVie Inc
17.3.2.1. Company Overview
17.3.2.2. Financial Overview
17.3.2.3. Product Portfolio
17.3.2.4. Business Strategies
17.3.2.5. Recent Developments
17.3.3. Amgen Inc
17.3.3.1. Company Overview
17.3.3.2. Financial Overview
17.3.3.3. Product Portfolio
17.3.3.4. Business Strategies
17.3.3.5. Recent Developments
17.3.4. AstraZeneca
17.3.4.1. Company Overview
17.3.4.2. Financial Overview
17.3.4.3. Product Portfolio
17.3.4.4. Business Strategies
17.3.4.5. Recent Developments
17.3.5. Eli Lilly and Company
17.3.5.1. Company Overview
17.3.5.2. Financial Overview
17.3.5.3. Product Portfolio
17.3.5.4. Business Strategies
17.3.5.5. Recent Developments
17.3.6. Johnson & Johnson Services, Inc.
17.3.6.1. Company Overview
17.3.6.2. Financial Overview
17.3.6.3. Product Portfolio
17.3.6.4. Business Strategies
17.3.6.5. Recent Developments
17.3.7. LEO Pharma A/S
17.3.7.1. Company Overview
17.3.7.2. Financial Overview
17.3.7.3. Product Portfolio
17.3.7.4. Business Strategies
17.3.7.5. Recent Developments
17.3.8. Merck & Co., Inc.,
17.3.8.1. Company Overview
17.3.8.2. Financial Overview
17.3.8.3. Product Portfolio
17.3.8.4. Business Strategies
17.3.8.5. Recent Developments
17.3.9. Novartis AG
17.3.9.1. Company Overview
17.3.9.2. Financial Overview
17.3.9.3. Product Portfolio
17.3.9.4. Business Strategies
17.3.9.5. Recent Developments
17.3.10. Boehringer Ingelheim Pharmaceuticals, Inc.
